NeuroJust Company Profile

Background

Overview

NeuroJust is a mental health clinic specializing in Transcranial Magnetic Stimulation (TMS) therapy, a non-invasive treatment for depression and other mood disorders. Established in 2021, the clinic operates in Metairie, Louisiana, with an additional location in Baton Rouge, Louisiana, opened in 2024.

Mission and Vision

NeuroJust's mission is to provide accessible, innovative, and medication-free treatments for mental health conditions, aiming to heal patients from mental illnesses and improve their quality of life. The clinic's vision is to offer alternative delivery methods for overall wellness, focusing on healing patients from mental illnesses and helping them achieve optimal health.

Primary Area of Focus

The clinic primarily focuses on TMS therapy, targeting underactive areas of the brain associated with mood regulation. This approach aims to provide long-term relief from depression and other mood disorders without the systemic side effects commonly associated with traditional medications.

Industry Significance

NeuroJust contributes to the growing field of non-invasive mental health treatments, offering an alternative to traditional pharmacological therapies. By providing TMS therapy, the clinic addresses the needs of patients seeking effective treatments without the side effects of medications.

Key Strategic Focus

Core Objectives

Accessibility: Making TMS therapy accessible to a broader patient base, including those who have not responded to traditional treatments.

Innovation: Utilizing advanced, FDA-approved technologies to provide effective mental health treatments.

Patient-Centered Care: Offering personalized treatment plans tailored to individual patient needs.

Specific Areas of Specialization

NeuroJust specializes in TMS therapy, focusing on treating depression, anxiety, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

Key Technologies Utilized

Transcranial Magnetic Stimulation (TMS): A non-invasive procedure that uses magnetic fields to stimulate underactive areas of the brain associated with mood regulation.

Primary Markets or Conditions Targeted

The clinic primarily targets individuals suffering from treatment-resistant depression and other mood disorders, offering an alternative to traditional medication-based treatments.

Financials and Funding

Funding History

Specific details regarding NeuroJust's funding history, total funds raised, and recent funding rounds are not publicly disclosed.

Notable Investors

Information about notable investors in NeuroJust is not publicly available.

Intended Utilization of Capital

While specific utilization details are not disclosed, it is likely that any raised capital would be directed towards expanding clinic operations, enhancing treatment technologies, and increasing patient outreach.

Pipeline Development

As a clinic specializing in TMS therapy, NeuroJust does not have a traditional product development pipeline. Instead, the clinic focuses on expanding its services and improving treatment outcomes for patients with mood disorders.

Technological Platform and Innovation

Proprietary Technologies

NeuroJust utilizes FDA-approved TMS technology to provide non-invasive treatments for depression and other mood disorders.

Significant Scientific Methods

TMS Therapy: A non-invasive procedure that uses magnetic fields to stimulate underactive areas of the brain associated with mood regulation.

AI-Driven Capabilities

There is no publicly available information indicating that NeuroJust employs AI-driven capabilities in its treatment processes.

Leadership Team

Key Executives

Jourdan Generes: Chief Executive Officer. Jourdan Generes is the CEO of NeuroJust, leading the clinic's mission to provide accessible and innovative mental health treatments.

Ryan Banquer: Chief Operating Officer. Ryan Banquer serves as the COO, overseeing the clinic's daily operations and ensuring the effective delivery of services.

Competitor Profile

Market Insights and Dynamics

The mental health treatment market is evolving, with a growing emphasis on non-invasive therapies like TMS. Patients are increasingly seeking alternatives to traditional medications due to concerns about side effects and efficacy.

Competitor Analysis

NeuroJust operates in a competitive landscape with several key players:

Neuronetics: Offers NeuroStar Advanced Therapy System, a TMS device for treating depression.

BrainsWay: Provides deep TMS technology for various indications, including depression.

Magstim: Develops TMS devices for therapeutic use.

MagVenture: Offers TMS devices for treating depression.

Strategic Collaborations and Partnerships

Specific details about NeuroJust's collaborations or partnerships are not publicly disclosed.

Operational Insights

NeuroJust differentiates itself by focusing on personalized, non-invasive treatments for mood disorders, providing an alternative to traditional medication-based therapies.

Strategic Opportunities and Future Directions

NeuroJust has opportunities to expand its services to additional locations, enhance treatment technologies, and increase patient outreach to further establish itself in the mental health treatment market.